Record Details

Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients

DIR@IMTECH: CSIR-Institute of Microbial Technology

View Archive Info
 
 
Field Value
 
Title Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients
 
Creator Rathore , Yogesh
Shukla , Jaya
Laroiya, Ishita
Deep , Amar
Lakhanpal , Tamanna
Kumar , Rajender
Singh , Harmandeep
Bal, Amanjit
Singh , Gurpreet
Thakur , Krishan Gopal
Mittal , B R
 
Subject QR Microbiology
 
Description Introduction: Receptors on breast cancer cells play a crucial role in the management of patients. Trastuzumab is a widely used drug for the treatment of HER2/neu expressing tumors. ImmunoPET with trastuzumab is not feasible due to slow pharmacokinetics. Fragment of antigen-binding (Fab) radiolabeled with positron emitters can be used for immunoPET.

Methods: Fab has been generated by papain digestion and conjugated with the bifunctional chelating agent NOTA. The SDS-PAGE and MALDI-TOF were used to see the integrity of Fab and conjugated Fab. In-vitro stability and target specificity for HER2/neu receptors were performed in plasma and receptor binding with bio-layer interferometry (BLI) techniques. Radiolabeling was standardized with 68GaCl3 and PET imaging was performed in seven patients showing 18F fluorodeoxyglucose (18F-FDG) uptake and correlated with HER2/neu expression by immunohistochemistry.

Results: Fab production was optimized at molar ratio 23:1 of trastuzumab and papain at 37 °C with a constant stirrer at 850 rpm for 22-24 h, at pH 8. Conjugation with NOTA was standardized at molar ratio 1:25 of trastuzumab Fab and NOTA. Molecular mass of trastuzumab Fab-NOTA was found approximately 46.3 kDa (~1/3 of intact antibody). Trastuzumab Fab-NOTA showed radiolabelling efficiency of 48-70% with incubation time 15 min at 37-40 °C and pH 4.5-5.0. BLI demonstrated the affinity of trastuzumab, trastuzumab Fab and trastuzumab Fab-NOTA towards HER2/neu receptor with KD of
 
Publisher Wolters Kluwer
 
Date 2022-04-01
 
Type Article
PeerReviewed
 
Relation https://journals.lww.com/nuclearmedicinecomm/Abstract/2022/04000/Development_68Ga_trastuzumab_Fab_and_bioevaluation.11.aspx
http://crdd.osdd.net/open/2992/
 
Identifier Rathore , Yogesh and Shukla , Jaya and Laroiya, Ishita and Deep , Amar and Lakhanpal , Tamanna and Kumar , Rajender and Singh , Harmandeep and Bal, Amanjit and Singh , Gurpreet and Thakur , Krishan Gopal and Mittal , B R (2022) Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients. Nuclear Medicine Communications , 43 (4). pp. 458-467.